Pfizer Ltd
Pfizer Ltd (PFIZER) last reported results for the quarter ended Jun 2026, with sales of ₹653 crore and net profit of ₹204 crore. The stock last traded at ₹3,808, a market capitalisation of ₹17,424 crore, on a P/E of 22.7. Over the past 52 weeks the stock has ranged between ₹3,731 and ₹5,578. Figures are as of 9 Oct 2026 and are not real time.
Pfizer Ltd share price and key metrics
- Current price
- ₹3,808
- Market cap
- ₹17,424 cr
- Stock P/E
- 22.7
- Book value
- ₹919
- ROE
- 18.0%
- ROCE
- 24.1%
- Dividend yield
- 1.97%
- 52w high / low
- 5578/3731
Metrics as of 9 Oct 2026. Not real time.
Track Pfizer Ltd
Cruxal reads every Pfizer Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Pfizer Ltd growth and returns
- 10 Years
- 2%
- 5 Years
- 2%
- 3 Years
- 1%
- TTM
- 11%
- 10 Years
- 10%
- 5 Years
- 9%
- 3 Years
- 8%
- TTM
- 14%
- 10 Years
- 7%
- 5 Years
- -7%
- 3 Years
- -1%
- 1 Year
- -28%
- 10 Years
- 17%
- 5 Years
- 18%
- 3 Years
- 16%
- Last Year
- 18%
Pfizer Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹653 cr, up 8.3% from ₹603 cr a year earlier. Net profit was ₹204 cr, up 6.3% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 589 | 538 | 592 | 603 | 642 | 645 | 629 | 653 |
| Expenses | 399 | 392 | 364 | 393 | 412 | 417 | 393 | 406 |
| Operating profit | 189 | 146 | 228 | 210 | 230 | 228 | 236 | 248 |
| OPM % | 32% | 27% | 38% | 35% | 36% | 35% | 38% | 38% |
| Other income | 43 | 43 | 217 | 67 | 42 | -20 | 50 | 45 |
| Interest | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 1 |
| Depreciation | 15 | 15 | 16 | 14 | 14 | 14 | 15 | 14 |
| Profit before tax | 215 | 172 | 426 | 260 | 255 | 192 | 269 | 277 |
| Tax % | 26% | 26% | 22% | 26% | 26% | 26% | 26% | 26% |
| Net profit | 158 | 128 | 331 | 192 | 189 | 142 | 200 | 204 |
| EPS (₹) | 34.61 | 27.89 | 72.34 | 41.91 | 41.32 | 31.00 | 43.68 | 44.70 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Pfizer Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,966 | 1,969 | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | 2,193 | 2,281 | 2,520 | 2,570 |
| Operating profit | 350 | 501 | 566 | 574 | 712 | 836 | 809 | 638 | 742 | 904 | 942 |
| OPM % | 18% | 25% | 27% | 27% | 32% | 32% | 33% | 29% | 33% | 36% | 37% |
| Net profit | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 768 | 722 | 735 |
| EPS (₹) | 73.62 | 78.71 | 93.79 | 111.29 | 108.77 | 133.90 | 136.38 | 120.52 | 167.79 | 157.92 | 160.70 |
TTM is the trailing twelve months to the most recent quarter.
Pfizer Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
| Reserves | 2,373 | 2,637 | 2,966 | 3,350 | 2,347 | 2,819 | 3,162 | 3,550 | 4,172 | 4,157 |
| Borrowings | 2 | 2 | 2 | 2 | 63 | 39 | 41 | 40 | 108 | 70 |
| Other liabilities | 840 | 1,004 | 926 | 1,007 | 810 | 997 | 752 | 593 | 585 | 649 |
| Total liabilities | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,922 |
| Fixed assets | 902 | 950 | 886 | 973 | 894 | 869 | 749 | 713 | 724 | 678 |
| CWIP | 15 | 1 | 0 | 1 | 3 | 1 | 8 | 0 | 8 | 20 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 2,343 | 2,739 | 3,054 | 3,432 | 2,369 | 3,030 | 3,244 | 3,516 | 4,180 | 4,224 |
| Total assets | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 | 4,922 |
As reported by the company. Total assets equal total liabilities by construction.
Pfizer Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 329 | 332 | 98 | 323 | 427 | 667 | 356 | 257 | 660 | 968 |
| Cash from investing | -250 | -238 | 35 | 1,530 | -469 | -575 | -36 | 54 | -71 | -562 |
| Cash from financing | -83 | -110 | -110 | -164 | -1,571 | -181 | -346 | -235 | -205 | -798 |
| Net cash flow | -3 | -17 | 23 | 1,690 | -1,613 | -88 | -26 | 75 | 383 | -392 |
| Free cash flow | 394 | 262 | 125 | 343 | 410 | 654 | 292 | 291 | 783 | 944 |
| CFO / operating profit | 146% | 105% | 59% | 93% | 89% | 107% | 81% | 64% | 110% | 105% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Pfizer Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 17% | 21% | 23% | 20% | 23% | 29% | 26% | 22% | 21% | 24% |
| Debtor days | 20 | 29 | 30 | 29 | 18 | 20 | 23 | 31 | 31 | 26 |
| Inventory days | 148 | 147 | 189 | 198 | 199 | 173 | 175 | 200 | 214 | 195 |
| Days payable | 178 | 245 | 213 | 197 | 130 | 102 | 91 | 77 | 68 | 89 |
| Cash conversion cycle | -10 | -69 | 6 | 31 | 87 | 91 | 107 | 154 | 177 | 132 |
| Working capital days | -47 | -57 | -16 | -8 | 3 | -14 | 1 | 24 | 23 | 9 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Pfizer Ltd shareholding pattern
Promoters held 63.92% at Jun 2026, broadly unchanged since Jun 2025. FIIs 1.65% and DIIs 17.80%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% |
| FIIs | 3.54% | 2.74% | 2.18% | 2.40% | 2.60% | 2.71% | 2.81% | 1.65% |
| DIIs | 16.03% | 16.80% | 17.10% | 17.23% | 17.11% | 17.05% | 16.89% | 17.80% |
| Public | 16.50% | 16.54% | 16.79% | 16.45% | 16.37% | 16.32% | 16.36% | 16.62% |
| No. of shareholders | 98,824 | 1,05,015 | 1,08,261 | 1,03,222 | 1,03,480 | 1,00,933 | 99,545 | 1,02,478 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Pfizer Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find attached Certificate under Regulation 74(5) of SEBI (Depositories and…
Read the full analysis - Pfizer Ltd publishes newspaper advertisements for transfer and dematerialisation of physical securitiesCompany Updatelow impact
Cruxal's analysis: Pfizer Ltd has issued newspaper advertisements regarding the transfer and…
Read the full analysis - Intimation for Closure of Trading Window.Insider Trading / SASTlow impact
- Pfizer Limited receives income tax transfer pricing penalty order of 1 crore 26 lakh 34 thousand 50 rupeesCompany Updatelow impact
Cruxal's analysis: Pfizer Limited has disclosed the receipt of an order from the Deputy/Additional…
Read the full analysis - Pfizer Limited announces resignation of Senior Director – Policy & Public AffairsCompany Updatelow impact
Cruxal's analysis: Pfizer Limited has informed the stock exchanges that Mr. Sharad Goswami, Senior Director…
Read the full analysis - Pfizer Limited to discontinue Minipress XL; to receive 131.38 crore lump sum payment from parentOthersmedium impact
Cruxal's analysis: Pfizer Limited has announced the immediate discontinuation of the marketing…
Read the full analysis - Pfizer Ltd announces special window for re-lodgement and dematerialisation of physical securities via newspaper publication on August 4, 2026Company Updatelow impact
Cruxal's analysis: Pfizer Ltd has published a newspaper advertisement on August 4, 2026, announcing a…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.